New Work SE

  • WKN: NWRK01
  • ISIN: DE000NWRK013
  • Land: Deutschland


Notiert in Xetra Frankfurt 
Index SDAX, TecDAX 
Branche Internet 
Letzte Dividende 2,59 Euro (für 2019) 
Rating Xetra 


Datum Maßnahme Gezeichnetes Kapital Aktienanzahl (in Mio. Stück)
2006  Umwandlung von GmbH in AG  52.050,00 €  52.050 
2006  Kapitalerhöhung  3.851.700,00 €  3.851.700 
2006  Kapitalerhöhung  5.201.700,00 €  5.201.700 
2009  Kapitalerhöhung  5.271.773,00 €  5.271.773 
2010  Kapitalerhöhung  5.272.447,00 €  5.272.447 
2011  Kapitalerhöhung  5.291.996,00 €  5.291.996 

Aktuelle Aktionärsstruktur

50,0% Burda Digital SE (DE)
5,5% Invesco Ltd. (US)
5,1% Virtus Opportunities Trust (US)
3,1% DWS Investment (DE)
3,0% Allianz Global Investors (DE)
33,3% Rest

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Adler Group S.A.

Investor Call
Q3 2021

30. November 2021

Aktuelle Research-Studie

clearvise AG

Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy

30. November 2021